An article in the August 21, 1998 issue of BioWorld Today should have said Celgene Corp., of Warren, N.J. — which received approval for thalidomide for complications of Hansen's disease, or leprosy — has developed the System for Thalidomide Education and Prescribing Safety (STEPS) program to ensure appropriate use of the drug and minimize the risk of severe birth defects, and physicians in that program are not barred from prescribing the drug for off-label uses.